NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Lupin Ranks #1 Globally in Pharma with 91/100 Score in S&P ESG Assessment 2025
Lupin has achieved the top global rank in the pharmaceutical sector in the 2025 S&P Global Corporate Sustainability Assessment (CSA) with a score of 91 out of 100. This score places Lupin in the top 1% of over 9,200 companies evaluated across 59 industries worldwide. Additionally, the company has been recognized as the leader across all sectors in India, surpassing both domestic and international peers. This marks Lupin's third consecutive year of inclusion in the S&P Sustainability Yearbook, reflecting strong governance and environmental stewardship.
முக்கிய அம்சங்கள்
Achieved a score of 91 out of 100 in the S&P Global Corporate Sustainability Assessment (CSA)Ranked No. 1 globally in the pharmaceutical industry and No. 1 across all sectors in IndiaPlaced within the top 1% of more than 9,200 companies assessed globallyIncluded in the Sustainability Yearbook 2026 for the third consecutive yearOne of only 848 companies to earn Yearbook inclusion out of 9,200+ assessed
👀 கவனிக்க வேண்டியவை
This recognition enhances Lupin's appeal to institutional and ESG-focused investors, potentially leading to increased capital inflows. Investors should consider this a positive indicator of the company's long-term operational resilience and governance standards.
Lupin Faces GST Inspection and Search at Registered Office in Mumbai
Lupin Limited has reported that the Maharashtra Goods & Service Tax Department initiated an inspection and search at its registered office on February 25, 2026. The search, conducted under Section 67 of the MGST Act, 2017, pertains to the verification of GST payments and Input Tax Credit (ITC) claims. The company is currently cooperating with officials and has stated that there is no immediate impact on its financial or operational activities. Investors should note that such inspections are procedural but can lead to future tax demands if discrepancies are found.
முக்கிய அம்சங்கள்
GST Department initiated search proceedings at Lupin's Mumbai office on February 25, 2026, at 11:50 AM.The inspection is being conducted under Section 67 of the Maharashtra GST Act, 2017.Authorities are seeking documents specifically related to GST payments and Input Tax Credit (ITC) claims.Lupin reports no current quantifiable impact on its financial or operational performance.The company is extending full cooperation and providing all necessary documentation to the tax officials.
👀 கவனிக்க வேண்டியவை
Investors should monitor for subsequent updates regarding any potential tax demands or litigation resulting from this search. No immediate action is required as operations remain unaffected, but tax-related developments can impact future cash flows.
Lupin Launches Brivaracetam Oral Solution in US Targeting $135 Million Market
Lupin Limited has received US FDA approval and commenced the launch of Brivaracetam Oral Solution (10 mg/mL) in the United States. The product is a generic equivalent of UCB's Briviact, used for treating partial-onset seizures in patients aged 1 month and older. According to IQVIA data, the annual sales for this product in the US were approximately USD 135 million as of December 2025. This launch further strengthens Lupin's presence in the US Central Nervous System (CNS) therapeutic segment.
முக்கிய அம்சங்கள்
Received US FDA approval for Brivaracetam Oral Solution 10 mg/mL ANDAProduct is the bioequivalent to Briviact Oral Solution by UCB, Inc.Targets a US market size estimated at USD 135 million per IQVIA MAT Dec 2025 dataIndicated for partial-onset seizures in patients 1 month of age and olderImmediate launch initiated in the United States market following approval
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of this product as it contributes to Lupin's high-margin US generic portfolio. The launch is a positive development for the company's CNS segment and overall US revenue growth.
Lupin Receives European Commission Approval for Biosimilar Ranibizumab (Ranluspec™)
Lupin has received marketing authorization from the European Commission for its biosimilar Ranibizumab, branded as Ranluspec™, available in vials and pre-filled syringes. The approval covers critical ophthalmic indications including wet age-related macular degeneration and diabetic macular edema. Lupin has partnered with Sandoz for commercialization across the European Union (excluding Germany) and with both Sandoz and Biogaran in France. This milestone validates Lupin's biotechnology capabilities and strengthens its portfolio in the high-growth biosimilars market.
முக்கிய அம்சங்கள்
European Commission approval granted for Ranluspec™ (biosimilar Ranibizumab) for multiple ophthalmic indications.Approval includes both vial and pre-filled syringe formats, enhancing delivery options for healthcare providers.Strategic commercialization partnership formed with Sandoz for the EU market, excluding Germany.Specific dual-partner commercialization strategy implemented for the French market with Sandoz and Biogaran.The product targets high-value therapeutic areas such as neovascular (wet) age-related macular degeneration and diabetic macular edema.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant positive development that expands Lupin's high-margin biologics portfolio in regulated markets. Monitor the commercial rollout and subsequent market share gains in Europe to assess long-term revenue impact.
Lupin Q3 FY26: Record Revenue of ₹7,168 Cr and EBITDA Margin Surges to 31.1%
Lupin delivered a robust Q3 FY26 performance with total revenue growing 24% YoY to INR 7,168 crores, driven by record US sales of USD 350 million. EBITDA margins expanded significantly to 31.1%, up 681 bps YoY, leading management to raise full-year margin guidance to 27%-28%. The US business benefited from new launches like Tolvaptan and Risperdal Consta, while the India prescription business grew 10.9% YoY. The company achieved a strong net cash position of INR 2,879 crores and received its first US biosimilar approval for Pegfilgrastim.
முக்கிய அம்சங்கள்
Revenue from operations grew 24% YoY to INR 7,168 crores, with US sales hitting a record USD 350 million.EBITDA margins reached 31.1%, an improvement of 681 bps YoY, driven by better product mix and cost efficiencies.India core prescription business grew 10.9% YoY, with Chronic segments now accounting for 67% of the portfolio.Emerging markets saw 42% YoY growth, led by a 99% local currency growth in Brazil following the Dapagliflozin launch.Management raised full-year EBITDA margin guidance to 27%-28% from the previous 25%-26% range.
👀 கவனிக்க வேண்டியவை
Investors should view the structural margin expansion and the entry into the US biosimilars market as significant long-term value drivers. The upward revision in guidance and strong cash generation support a positive outlook on the stock.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Lupin Partners with Spektus to Launch Novel Antidepressant DeslaFlex in Canada
Lupin Limited has signed a strategic license and supply agreement with Spektus Pharma to commercialize DeslaFlex™, a novel antidepressant, in the Canadian market. DeslaFlex™ utilizes the proprietary Flexitab™ oral drug-delivery platform to treat Major Depressive Disorder with enhanced dosing flexibility. This partnership leverages Lupin's established commercial infrastructure in Canada to expand its Central Nervous System (CNS) portfolio. The collaboration is part of Lupin's broader strategy to introduce value-added, physician-endorsed specialty therapies in developed markets.
முக்கிய அம்சங்கள்
Exclusive license and supply agreement for the commercialization of DeslaFlex™ in Canada.Targeted at Major Depressive Disorder using the proprietary Flexitab™ drug-delivery platform.Strengthens Lupin's CNS portfolio and global specialty business footprint.Lupin maintains a global presence with 15 manufacturing sites and 7 research centers.The agreement marks Spektus Pharma's transition from development to commercial execution.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial rollout and market share gains of DeslaFlex™ in Canada as it represents a high-margin specialty product addition. This move reinforces Lupin's growth potential in the CNS segment within developed markets.
Anand Kripalu Joins Lupin Board as Independent Director
Lupin Limited has appointed Anand Kripalu as an Independent Director to its Board, effective February 13, 2026. Kripalu brings over 30 years of leadership experience from the FMCG sector, having served as MD and Global CEO of EPL Limited and CEO of Diageo India. His extensive background includes 20 years at Unilever and leadership roles at Mondelez International. This appointment is expected to strengthen Lupin's strategic oversight and global market positioning.
முக்கிய அம்சங்கள்
Anand Kripalu appointed as Independent Director with over 30 years of FMCG leadership experience.Previously served as Managing Director and Global CEO of EPL Limited until December 31, 2025.Held senior leadership roles at Diageo India (MD & CEO) and Mondelez International (President - India & SE Asia).Currently serves on the boards of Swiggy Limited and United Breweries Limited.Educational background includes degrees from IIT Madras and IIM Calcutta, plus an AMP from Wharton.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive corporate governance move that adds significant consumer-market expertise to the board. No immediate action is required, but the appointment may help refine Lupin's domestic and global branding strategies.
Lupin Q3 FY26: Net Profit jumps 38% to ₹1,176 Cr; EBITDA margins expand to 31.1%
Lupin reported a robust performance for Q3 FY26, with consolidated revenue growing 26% YoY to ₹7,101 crore, primarily driven by a 46% surge in the US market. EBITDA margins saw a significant expansion to 31.1% from 24.3% in the previous year, reflecting a superior product mix and operational efficiencies. The US business achieved a record quarterly high of $350 million, supported by key launches like gRisperdal Consta. While India growth was moderate at 6%, the company maintained its leadership in chronic segments and improved its net cash position.
முக்கிய அம்சங்கள்
Consolidated Sales grew 26% YoY to ₹71,005 mn, while EBITDA surged 62% YoY to ₹22,095 mn.US sales reached a record $350 mn, growing 46% YoY, driven by complex generic launches and base business momentum.EBITDA margins expanded significantly to 31.1% compared to 24.3% in Q3 FY25.The company is now in a net cash position with a Net Debt to Equity ratio of -0.14.Received US FDA approval for Armlupeg (biosimilar) and successful inspection outcomes (NAI/VAI) for Nagpur and Aurangabad sites.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strong performance, particularly the massive margin expansion and record US sales. The stock remains a key pick in the pharma sector as it successfully pivots toward complex generics and biosimilars.
Lupin Q3 FY26 Results: PAT Up 37% YoY to ₹1,181 Cr; US Sales Surge 54%
Lupin reported a robust performance for Q3 FY26, with consolidated sales growing 26.4% YoY to ₹7,101 crore, driven by record US sales of $350 million. EBITDA margins saw a significant expansion of 840 bps YoY to 33.5%, although they moderated slightly from the previous quarter. Despite a one-time exceptional charge of ₹427 crore, Profit After Tax (PAT) grew 37.4% YoY to ₹1,181 crore. The company remains net debt-free with a strong cash position of ₹2,879 crore.
முக்கிய அம்சங்கள்
Consolidated Sales grew 26.4% YoY to ₹71,005 Mn, led by a 54% surge in US revenue.EBITDA increased 68.6% YoY to ₹23,766 Mn with margins expanding to 33.5% from 25.1% YoY.PAT rose 37.4% YoY to ₹11,805 Mn, even after accounting for a ₹4,266 Mn exceptional item.India formulation sales grew 10.9% YoY, while Global API sales declined 24.1% YoY.Net Cash position stands at ₹28,793 Mn with a Net Debt to Equity ratio of -0.14.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong US growth and significant margin expansion as key positives. While API sales were weak, the company's robust cash position and leadership in US generics support a positive long-term outlook.
Lupin Q3 FY26 Results: Consolidated Revenue Up 24.3% YoY; Impacted by ₹6.34B Exceptional Charges
Lupin reported a strong operational performance for Q3 FY26 with consolidated revenue growing 24.3% YoY to ₹71,675.2 million. However, the bottom line was significantly impacted by exceptional items totaling ₹6,338.4 million, including a ₹4,493.9 million ($50M) provision for US antitrust litigation and a ₹1,348.1 million ($15M) settlement for Mirabegron ER Tablets. Excluding these one-time costs, standalone profit before tax grew 16% YoY to ₹15,017.8 million, reflecting healthy core business momentum despite regulatory and legal headwinds.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations increased 24.3% YoY to ₹71,675.2 million.Standalone Profit before exceptional items and tax grew 16% YoY to ₹15,017.8 million.Recognized a ₹4,493.9 million ($50 million) provision for settling class-action antitrust litigations in the US.Agreed to a one-time settlement payment of ₹1,348.1 million ($15 million) for Mirabegron ER Tablets dispute.Accounted for ₹496.4 million in incremental costs due to the implementation of New Labour Codes effective November 2025.
👀 கவனிக்க வேண்டியவை
Investors should focus on the robust 24% revenue growth and operational margins while treating the legal provisions as necessary one-time costs to clear litigation overhangs. The stock may see short-term volatility due to the net profit dip, but the underlying business strength remains intact.
Lupin Settles Mirabegron Patent Dispute with Astellas for USD 90 Million
Lupin Limited and its US subsidiary have entered into a settlement and license agreement with Astellas Pharma to resolve patent litigation regarding the drug Mirabegron. Under the agreement, Lupin will pay Astellas a total of USD 90 million, which includes a USD 75 million prepaid option payment. Additionally, Lupin will pay a per-unit license fee for products sold through September 2027. This settlement is significant as it removes legal uncertainty and allows Lupin to continue marketing the product.
முக்கிய அம்சங்கள்
Settlement resolves long-standing patent infringement dispute with Astellas Pharma regarding 'Mirabegron'.Lupin to pay a total of USD 90 million, including a USD 75 million Prepaid Option Payment.Agreement includes a Prepaid Per Unit License Fee for each unit sold through September 2027.The settlement ensures Lupin can continue to sell its Mirabegron product without further litigation risk.
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of the USD 90 million cash outflow on the upcoming quarterly earnings and margins. While the payout is substantial, the resolution of legal risk for a key product provides long-term clarity for the US generic portfolio.
Lupin Launches Topiramate Extended-Release Capsules in US; $164M Market Opportunity
Lupin Limited has launched Topiramate Extended-Release Capsules in the United States following U.S. FDA approval of its Abbreviated New Drug Application (ANDA). The product is a generic version of Trokendi XR® and is available in four strengths ranging from 25 mg to 200 mg. The addressable market for this product in the U.S. is estimated at USD 164 million annually according to IQVIA data. This launch strengthens Lupin's portfolio in the Central Nervous System (CNS) therapeutic segment, a key growth area for the company.
முக்கிய அம்சங்கள்
Launched Topiramate Extended-Release Capsules in 25 mg, 50 mg, 100 mg, and 200 mg strengths.Product is bioequivalent to the reference drug Trokendi XR® by Supernus Pharmaceuticals.Estimated annual sales for the product in the U.S. market are USD 164 million as of December 2025.Indicated for the treatment of seizures in patients 6 years and older and migraine prevention in patients 12 years and older.
👀 கவனிக்க வேண்டியவை
Investors should monitor Lupin's ability to capture market share in the CNS segment, as this launch provides a steady revenue stream in the U.S. generics market. The $164 million market size offers a meaningful incremental growth opportunity for the company's North American operations.
Lupin Launches Generic Sprycel (Dasatinib) in US Targeting $930 Million Market
Lupin Limited has launched Dasatinib Tablets in the United States, a generic version of Bristol-Myers Squibb's Sprycel, following US FDA approval. Developed in partnership with Pharmascience Inc., the product is available in six strengths ranging from 20 mg to 140 mg. This launch addresses a significant market opportunity, as the reference drug Sprycel had estimated annual US sales of USD 930 million as of October 2025. The medication is used for treating Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia in both adults and children.
முக்கிய அம்சங்கள்
Launched Dasatinib Tablets in 20mg, 50mg, 70mg, 80mg, 100mg, and 140mg strengths in the USTargets a market with estimated annual sales of USD 930 million (IQVIA MAT Oct 2025)Product developed in collaboration with Canadian firm Pharmascience Inc.Indicated for multiple leukemia treatments including Ph+ CML and Ph+ ALL in adults and pediatric patients
👀 கவனிக்க வேண்டியவை
This high-value generic launch is expected to bolster Lupin's US revenue and oncology portfolio. Investors should track the company's ability to capture market share from the innovator and other generic entrants.
Lupin Partners with TB Alliance to Advance Telacebec for Tuberculosis and Mycobacterial Diseases
Lupin has entered into a strategic collaboration with TB Alliance to advance the clinical development and commercialization of Telacebec (formerly Q203). The drug targets major mycobacterial diseases including tuberculosis, leprosy, and Buruli ulcer. While TB Alliance leads the development process, Lupin will leverage its global manufacturing expertise and distribution network across 100+ markets to ensure supply. This partnership strengthens Lupin's position in the anti-infective therapy area and addresses significant unmet medical needs globally.
முக்கிய அம்சங்கள்
Strategic collaboration for Telacebec (Q203) targeting TB, leprosy, and Buruli ulcerLupin to provide global manufacturing, regulatory affairs, and supply chain expertiseTB Alliance to continue leading the clinical development process of the investigational drugLupin operates 15 manufacturing sites and 7 research centers to support global accessCollaboration aims to provide equitable access to advanced treatments in over 100 markets
👀 கவனிக்க வேண்டியவை
Investors should monitor the clinical trial progress of Telacebec as it represents a significant addition to Lupin's anti-infective pipeline. This partnership enhances Lupin's long-term growth prospects in specialized therapy areas and its global ESG standing.
Lupin Achieves Highest Double 'A' ESG Rating from CDP for Climate and Water
Lupin Limited has been awarded the highest 'A' leadership rating by the Climate Disclosure Project (CDP) for both Climate Change and Water Security in 2026. This marks a steady improvement from its 2024 'A-' ratings and 2023 ratings of 'B' for climate and 'C' for water. Furthermore, the company reported an S&P Global ESG score of 91 for 2025, placing it in an elite global bracket of companies surpassing the 90-point threshold. These achievements reflect Lupin's enhanced focus on sustainability, which is increasingly vital for attracting global institutional capital.
முக்கிய அம்சங்கள்
Achieved double 'A' leadership rating from CDP for Climate Change and Water Security in 2026.Significant multi-year improvement from 2023 ratings of 'B' (Climate) and 'C' (Water).Secured a best-in-class S&P Global ESG score of 91 in 2025.Recognition positions Lupin as a global leader in environmental transparency and risk management.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive fundamental development that enhances Lupin's attractiveness to ESG-mandated institutional funds. While it doesn't impact short-term earnings, it strengthens the company's long-term risk profile and global reputation.
Lupin Signs Licensing Deal with Galenicum for Semaglutide in 23 Global Markets
Lupin Limited has entered into a strategic licensing and supply agreement with Galenicum Health for injectable Semaglutide, a high-demand GLP-1 receptor agonist. The partnership covers 23 countries across Canada, Europe, Southeast Asia, and Latin America, positioning Lupin to capture growth in the global diabetes and obesity markets. While Galenicum will manage manufacturing and development, Lupin will leverage its commercial infrastructure for regulatory approvals and distribution. This move significantly strengthens Lupin's specialty portfolio and expands its international footprint in high-growth therapeutic areas.
முக்கிய அம்சங்கள்
Agreement covers the commercialization of injectable Semaglutide in 23 countries globally.Target markets include major regions such as Canada, Europe, Southeast Asia, and Latin America.Lupin will handle all regulatory submissions, approvals, and distribution while Galenicum manages manufacturing.Strategic entry into the GLP-1 market, which is currently one of the fastest-growing segments in pharma for diabetes and obesity.Lupin's subsidiary, Lupin Atlantis Holdings SA (LAHSA), will execute the agreement.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strong strategic move into the lucrative GLP-1 market. Monitor the timeline for regulatory approvals and product launches in the specified 23 countries as these will be the primary drivers for future revenue growth from this deal.
Lupin Appoints FMCG Veteran Anand Kripalu as Independent Director for 5-Year Term
Lupin Limited has announced the appointment of Mr. Anand Kripalu as an Additional Director (Non-Executive, Independent) effective February 1, 2026. Mr. Kripalu brings over 30 years of extensive industry experience, having previously served as MD & CEO of Diageo India and held senior leadership roles at Mondelez and Unilever. His appointment is for a five-year term ending January 31, 2031, subject to shareholder approval. This move is expected to enhance the board's strategic depth given his track record in global consumer-facing industries.
முக்கிய அம்சங்கள்
Appointment of Mr. Anand Kripalu as Independent Director for a 5-year term starting February 1, 2026Over 30 years of leadership experience in FMCG, including roles at Diageo, Mondelez, and UnileverEducational background includes B.Tech from IIT Madras, MBA from IIM Calcutta, and AMP from WhartonCurrently serves as Executive Director of EPL Limited and holds board positions at Swiggy and United BreweriesThe appointment was unanimously approved by the Board based on the Nomination and Remuneration Committee's recommendation
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward strengthening corporate governance and strategic oversight. No immediate portfolio action is required based on this board-level appointment.
Lupin Extends Timeline for VISUfarma B.V. Acquisition to February 2026
Lupin Limited's wholly owned subsidiary, Nanomi B.V., has announced a delay in the acquisition of 100% share capital of VISUfarma B.V., Netherlands. The transaction, which was originally expected to be consummated by the end of calendar year 2025, is now slated for completion by February 28, 2026. The acquisition process is currently in progress and remains subject to specific closing conditions. This update follows the initial definitive agreement signed on September 29, 2025.
முக்கிய அம்சங்கள்
Acquisition of 100% share capital of Amsterdam-based VISUfarma B.V. by Nanomi B.V.Completion deadline extended from December 31, 2025, to February 28, 2026.The transaction is currently in progress and pending certain closing conditions.Initial definitive agreement for the acquisition was signed on September 29, 2025.
👀 கவனிக்க வேண்டியவை
Investors should view this as a minor administrative delay in the acquisition process. Monitor for the final completion announcement by February 2026 to ensure the strategic expansion into the European market remains on track.
Lupin Signs Exclusive Deal for First-in-Class Fortnightly GLP-1 Agonist in India
Lupin has entered into an exclusive licensing agreement with Gan & Lee Pharmaceuticals to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. The drug is a potential first-in-class fortnightly (once every two weeks) injection for Type 2 diabetes and obesity management. This partnership targets a massive addressable market in India, which includes approximately 90 million diabetics and 174 million overweight adults. By offering a 50% reduction in injection frequency compared to weekly alternatives, Lupin aims to capture significant market share in the high-growth metabolic health segment.
முக்கிய அம்சங்கள்
Exclusive rights to commercialize Bofanglutide, a fortnightly GLP-1 receptor agonist, in the Indian market.Reduces injection frequency by 50% compared to existing weekly GLP-1 injectable alternatives.Targets a massive patient base of 90 million diabetics and 174 million overweight adults in India.Clinical data indicates weight loss efficacy comparable to or better than current GLP-1 class drugs.Strengthens Lupin's chronic disease portfolio and establishes a foothold in the lucrative obesity segment.
👀 கவனிக்க வேண்டியவை
Investors should monitor the regulatory approval timeline for Bofanglutide in India as it represents a significant growth lever for Lupin's domestic formulations business. The unique fortnightly dosing provides a strong competitive moat in the rapidly expanding GLP-1 market.
Lupin Signs Exclusive Licensing Deal for Plasil® in Philippines and Brazil
Lupin Limited has entered into an exclusive licensing agreement with Italy-based Neopharmed Gentili S.p.A for the gastroenterology brand Plasil® (metoclopramide). The agreement covers marketing and promotional rights in the Philippines and Brazil through Lupin's subsidiaries, Multicare Pharmaceuticals and MedQuimica. A key strategic component includes shifting the production for the Brazilian market to Lupin's own Medquimica manufacturing facility. This move is designed to strengthen Lupin's gastrointestinal portfolio and presence in high-growth emerging markets.
முக்கிய அம்சங்கள்
Exclusive licensing for the gastroenterology brand Plasil® in the Philippines and Brazil.Partnership with Neopharmed Gentili S.p.A to leverage local commercial capabilities.Localization of manufacturing for the Brazilian market at Lupin's Medquimica facility.Strategic expansion into the anti-emetic and motility disorder treatment segment in emerging markets.
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue contribution from these new territories as Lupin leverages its existing distribution network. The shift to in-house manufacturing in Brazil could potentially lead to better margins for this product line over time.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
